WuXi Biologics has begun building a biologics conjugation and drug product plant in China to support antibody-drug conjugate (ADC) services. To be known as DP3, the 6,000m2 facility will be the third drug product site for the contract development and manufacturing organization (CDMO) and is expected to be open next year. The facility in Wuxi City, China will offer both clinical and commercial antibody-drug conjugate (ADC) services and will be an extension of similar conjugation and fill/finish operations at WuXi’s…